12:00 AM
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GS-6624: Phase II started

Last quarter, Gilead began a double-blind, U.S. Phase II trial to compare 200 and 700 mg GS-6624 in combination with FOLFIRI vs. FOLFIRI...

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >